BTIG raised the firm’s price target on Exagen (XGN) to $9 from $5 and keeps a Buy rating on the shares. The company delivered a solid Q1 revenue beat driven by strength in average sales price expansion which exceeded the firm’s expectations, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN: